PE20150190A1 - Formulacion farmaceutica - Google Patents

Formulacion farmaceutica

Info

Publication number
PE20150190A1
PE20150190A1 PE2014002385A PE2014002385A PE20150190A1 PE 20150190 A1 PE20150190 A1 PE 20150190A1 PE 2014002385 A PE2014002385 A PE 2014002385A PE 2014002385 A PE2014002385 A PE 2014002385A PE 20150190 A1 PE20150190 A1 PE 20150190A1
Authority
PE
Peru
Prior art keywords
pharmaceutical formulation
antibody
present
high concentration
formulation including
Prior art date
Application number
PE2014002385A
Other languages
English (en)
Inventor
Andrew Jeffrey Yates
James Gregory Clipstone
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of PE20150190A1 publication Critical patent/PE20150190A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

LA PRESENTE INVENCION SE REFIERE A METODOS Y MEDIOS PARA REDUCIR LA VISCOSIDAD DE UNA FORMULACION FARMACEUTICA QUE COMPRENDE UN ANTICUERPO U OTRA PROTEINA TERAPEUTICA A UNA ELEVADA CONCENTRACION. LA PRESENTE INVENCION PROPORCIONA UNA FORMULACION FARMACEUTICA LIQUIDA QUE COMPRENDE UN ANTICUERPO A CONCENTRACION ELEVADA CON UNA VISCOSIDAD REDUCIDA QUE NO IMPIDE SU PROCESAMIENTO NI LA INYECCION DE LA FORMULACION FARMACEUTICA. EL ANTICUERPO ES EPRATUZUMAB A UNA CONCENTRACION DE 200 A 400 MG/ML
PE2014002385A 2012-06-21 2013-06-20 Formulacion farmaceutica PE20150190A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21

Publications (1)

Publication Number Publication Date
PE20150190A1 true PE20150190A1 (es) 2015-02-13

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002385A PE20150190A1 (es) 2012-06-21 2013-06-20 Formulacion farmaceutica

Country Status (25)

Country Link
US (1) US20150150979A1 (es)
EP (1) EP2864356A1 (es)
JP (1) JP6157611B2 (es)
KR (1) KR20150032941A (es)
CN (1) CN104520326A (es)
AR (1) AR091530A1 (es)
AU (1) AU2013279347A1 (es)
BR (1) BR112014031841A2 (es)
CA (1) CA2876012A1 (es)
CL (1) CL2014003283A1 (es)
CO (1) CO7170174A2 (es)
EA (1) EA201590061A1 (es)
EC (1) ECSP15002095A (es)
HK (1) HK1205146A1 (es)
IL (1) IL235921A0 (es)
MA (1) MA37777B1 (es)
MX (1) MX2014014717A (es)
NZ (1) NZ702342A (es)
PE (1) PE20150190A1 (es)
PH (1) PH12014502596A1 (es)
SG (1) SG11201407779YA (es)
TN (1) TN2014000498A1 (es)
TW (1) TW201406398A (es)
WO (1) WO2013190047A1 (es)
ZA (1) ZA201409020B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102435648B1 (ko) 2013-09-11 2022-08-25 이글 바이오로직스 인코퍼레이티드 점도저하제를 함유하는 액체 단백질 제형
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
CA3109613A1 (en) 2016-05-28 2017-12-07 Rajiv Gandhi Centre For Biotechnology, An Autonomous Institute Under The Department Of Bio-Technology, Government Of India Uttroside b and derivatives thereof as therapeutics for hepatocellular carcinoma
KR20190078572A (ko) * 2016-10-31 2019-07-04 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
AU2018207367B2 (en) 2017-01-11 2024-02-15 Celltrion Inc. Stable Liquid Formula
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
EP4247386A1 (en) * 2020-11-18 2023-09-27 Bexson Biomedical, Inc. Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1324776B2 (en) * 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
ES2349779T5 (es) * 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
BRPI0608855A2 (pt) * 2005-03-08 2010-02-02 Pharmacia & Upjohn Co Llc composições de anticorpo anti - madcam processo para a preparação das mesmas e uso de anticorpo anti - madcam
WO2008086395A2 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
PT2170390T (pt) * 2007-06-14 2019-02-12 Biogen Ma Inc Formulações com anticorpo natalizumab
MX2012012743A (es) * 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
ME02819B (me) * 2010-05-14 2018-01-20 Amgen Inc Formulacije sa visokom koncentracijom antitijela
SG186421A1 (en) * 2010-07-02 2013-01-30 Medimmune Llc Antibody formulations
EP2694708A4 (en) * 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS WITH REDUCED VISCOSITY
CN103501825B (zh) * 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩

Also Published As

Publication number Publication date
AR091530A1 (es) 2015-02-11
NZ702342A (en) 2016-07-29
ZA201409020B (en) 2016-09-28
TN2014000498A1 (en) 2016-03-30
IL235921A0 (en) 2015-01-29
EA201590061A1 (ru) 2015-05-29
US20150150979A1 (en) 2015-06-04
CO7170174A2 (es) 2015-01-28
MX2014014717A (es) 2015-03-06
JP6157611B2 (ja) 2017-07-05
MA37777B1 (fr) 2017-07-31
AU2013279347A1 (en) 2014-12-18
CA2876012A1 (en) 2013-12-27
CL2014003283A1 (es) 2016-04-01
WO2013190047A1 (en) 2013-12-27
HK1205146A1 (en) 2015-12-11
EP2864356A1 (en) 2015-04-29
MA20150436A1 (fr) 2015-11-30
BR112014031841A2 (pt) 2017-06-27
JP2015520206A (ja) 2015-07-16
SG11201407779YA (en) 2015-02-27
KR20150032941A (ko) 2015-03-31
ECSP15002095A (es) 2015-11-30
PH12014502596A1 (en) 2015-01-12
CN104520326A (zh) 2015-04-15
TW201406398A (zh) 2014-02-16

Similar Documents

Publication Publication Date Title
PE20150190A1 (es) Formulacion farmaceutica
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
BR112018002196A2 (pt) formulação anti-ifnar1 estável
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
GT201400285A (es) Formulacion de anticuerpos
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
AR098168A1 (es) Formulación estable de insulina glulisina
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
CO7270463A2 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición
CL2015003738A1 (es) Formulación líquida estable de amg-416 (velcalcetida)
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
BR112019023981A2 (pt) injeção de octreotida
CL2016000944A1 (es) Nueva formulación de ganadotropinas
BR112014021870A2 (pt) formulação de anticorpos anti-selectina p

Legal Events

Date Code Title Description
FD Application declared void or lapsed